Physician profile
Premal Lulla
NPI 1023343357
$11,644.94
in general payments reported to CMS, 2019-2025
28 companies · $3,874 in 2025
The $3,874 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $665 · 2020: $73.83 · 2021: $1,658 · 2023: $1,370 · 2024: $4,004 · 2025: $3,874.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,840 · Food and Beverage: $268 · Travel and Lodging: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,840.00 |
| Food and Beverage | $267.92 |
| Travel and Lodging | $140.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $4,044.77 | 2023-2025 | Yescarta |
| Novartis Pharmaceuticals Corporation | $3,965.07 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $1,550.00 | 2021 | |
| Janssen Biotech, INC. | $1,364.28 | 2019-2023 | Tecvayli |
| Dova Pharmaceuticals | $77.47 | 2019 | |
| Amgen INC. | $66.44 | 2019-2021 | |
| Incyte Corporation | $63.67 | 2019-2020 | |
| Celgene Corporation | $60.35 | 2019 | |
| Servier Pharmaceuticals LLC | $49.53 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.31 | 2019 | |
| Merck Sharp & Dohme LLC | $34.75 | 2019 | |
| Seagen INC. | $34.15 | 2019-2020 | |
| Rigel Pharmaceuticals, INC. | $32.28 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $25.65 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.71 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $24.49 | 2019 | |
| Genzyme Corporation | $24.42 | 2019 | |
| Sanofi-Aventis U.S. LLC | $22.94 | 2021 | |
| Astellas Pharma US INC | $21.69 | 2019 | |
| Coherus Oncology, INC. | $21.51 | 2021 | |
| Pfizer INC. | $20.53 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $17.00 | 2019 | |
| Agios Pharmaceuticals, INC. | $14.94 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.65 | 2019 | |
| Array Biopharma INC | $12.69 | 2019 | |
| Jazz Pharmaceuticals INC. | $12.65 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Premal Lulla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.